Skip to main content
SpringerLink
Log in

Idiopathisches Parkinson-Syndrom (IPS)

  • Living reference work entry
  • First Online:
Book cover Klinische Neurologie

Part of the book series: Springer Reference Medizin ((SRM))

  • 769 Accesses

Zusammenfassung

Die Kardinalsymptome des Parkinsonismus Bradykinese, Rigor, Tremor und Einschränkung der posturalen Reflexe treten häufig auf und nehmen im Alter zu. Nur ein Teil aller Patienten mit Parkinsonismus leidet tatsächlich an dem idiopathischen Parkinson-Syndrom im engeren Sinne („Parkinson’s disease“ – Morbus Parkinson), das im Gegensatz zu sog. Parkinson-Plus-Syndromen in der Regel zumindest während der ersten Jahre gut bis sehr gut medikamentös behandelt werden kann. Das idiopathische Parkinson-Syndrom war die erste degenerative Erkrankung des ZNS, deren grundlegende Pathophysiologie verstanden worden ist. Die Erkenntnis des Dopamindefizits im Striatum führte zur Basis der medikamentösen Parkinson-Therapie, der Dopaminsubstitution durch Dopaminergika (L-Dopa als Vorstufe von Dopamin, Dopaminagonisten). Im Langzeitverlauf treten Komplikationen wie Wirkungsschwankungen von L-Dopa, Dyskinesien, vegetative und neuropsychiatrische Probleme auf, die einer spezifischen Behandlung zugeführt werden müssen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Literatur

  • Ancoli-Israel S, Martin JL, Gehrman P et al (2003) Effect of light on agitation in institutionalized patients with severe Alzheimer disease. Am J Geriatr Psychiatry 11:194–203

    Article  PubMed  Google Scholar 

  • Baezner H, Oster M, Henning O, Cohen S, Hennerici MG (2001) Amantadine increases gait steadiness in frontal gait disorder due to subcortical vascular encephalopathy: a double-blind randomized placebo-controlled trial based on quantitative gait analysis. Cerebrovasc Dis 11(3):235–244

    Article  CAS  PubMed  Google Scholar 

  • Ballard CG, O’Brien JT, Reichelt K, Perry EK (2002) Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: Te results of a double-blind, placebo-controlled trial with Melissa. J Clin Psychiatry 63:553–558

    Article  PubMed  Google Scholar 

  • Benamer TS, Patterson J, Grosset DG et al (2000) Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 15:503–510

    Article  CAS  PubMed  Google Scholar 

  • Bennett DA, Beckett LA, Murray AM et al (1996) Prevalence of parkinsonian signs and associated mortality in a community population of older people. N Engl J Med 334:71–76

    Article  CAS  PubMed  Google Scholar 

  • Bergman H, Wichmann T, DeLong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249:1436–1438

    Article  CAS  PubMed  Google Scholar 

  • Bonuccelli U, Ceravolo R, Salvetti S et al (1997) Clozapine in Parkinson’s disease tremor. Effects of acute and chronic administration. Neurology 49:1587–1590

    Article  CAS  PubMed  Google Scholar 

  • Burn D, Emre M, McKeith I et al (2006) Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord 21:1899–1907

    Article  PubMed  Google Scholar 

  • Campos-Sousa RN, Quagliato E, da Silva BB, de Carvalho RM Jr, Ribeiro SC, de Carvalho DF (2003) Urinary symptoms in Parkinson’s disease: prevalence and associated factors. Arq Neuropsiquiatr 61:359–363

    Article  PubMed  Google Scholar 

  • Ceballos-Baumann A, Ebersbach G (Hrsg) (2017) Aktivierende Therapien bei Parkinson-Syndromen, 3. Aufl. Thieme, Stuttgart

    Google Scholar 

  • Ceballos-Baumann AO (2005) Idiopathisches Parkinson-Syndrom: Grundlagen, Medikamente, Therapieeinleitung. In: Ceballos-Baumann AO, Conrad B (Hrsg) Bewegungsstörungen in der Neurologie. Thieme, Stuttgart, S 33–70

    Google Scholar 

  • Ceballos-Baumann A (2015) Schmerzen und Missempfindungen bei Parkinson-Patienten. Nervenheilkunde 34:167–173

    Google Scholar 

  • Ceballos-Baumann AO, Boecker H (2000) Tremor – new therapy options. Internist (Berl) 41:1353–1362

    Article  Google Scholar 

  • Ceballos-Baumann A, Gündel H (2006) Bewegungsstörungen. In: Henningsen P, Gündel H, Ceballos-Baumann A (Hrsg) Neuropsychosomatik. Schattauer, Stuttgart

    Google Scholar 

  • Ceballos-Baumann AO, von Kummer R, Eckert W, Weicker H (1990) Controlled-release levodopa/benserazide (Madopar HBS): clinical observations and levodopa and dopa mine plasma concentrations in fluctuating parkinsonian patients. J Neurol 237:24–28

    Article  CAS  PubMed  Google Scholar 

  • Ceballos-Baumann A, Ebersbach G, Schroeteler F, Ziegler K et al (2012) Aktivierende Therapie bei Parkinsonsyndromen, 2. Aufl. Thieme, Stuttgart

    Google Scholar 

  • Chan PL, Nutt JG, Holford NH (2007) Levodopa slows progression of Parkinson’s disease: external validation by clinical trial simulation. Pharm Res 24:791–802

    Article  CAS  PubMed  Google Scholar 

  • Chan HF, Kukkle PL, Merello M, Lim SY, Poon YY, Moro E (2013) Amantadine improves gait in PD patients with STN stimulation. Parkinsonism Relat Disord 19(3):316–319

    Article  PubMed  Google Scholar 

  • Coelho M, Marti MJ, Sampaio C, Ferreira JJ, Valldeoriola F, Rosa MM et al (2015) Dementia and severity of parkinsonism determines the handicap of patients in late-stage Parkinson’s disease: the Barcelona-Lisbon cohort. Eur J Neurol 22(2):305–312. https://doi.org/10.1111/ene.12567

    Article  CAS  PubMed  Google Scholar 

  • Deep-Brain-Stimulation-Study-Group (2001) Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson’s disease. N Engl J Med 345:956–963

    Article  Google Scholar 

  • Deuschl G, Schade-Brittinger C, Krack P et al (2006) A randomized trial of deep-brain stimulation for Parkinson’s disease. N Engl J Med 355:896–908

    Article  CAS  PubMed  Google Scholar 

  • Dorsey ER, Constantinescu R, Thompson JP et al (2007) Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68:384–386

    Article  CAS  PubMed  Google Scholar 

  • Dorsey ER, Shererb T, Okunc MS et Bloem BR. The Emerging Evidence of the Parkinson Pandemic. J Parkinsons Dis 8 (2018) S3–S8 S3. https://doi.org/10.3233/JPD-181474

    Article  PubMed  PubMed Central  Google Scholar 

  • Ebersbach G, Ebersbach A, Edler D et al (2010) Comparing exercise in Parkinson’s disease – the Berlin LSVT(R)BIG study. Mov Disord 25(12):1902–1908

    Article  PubMed  Google Scholar 

  • Emre M, Aarsland D, Albanese A et al (2004) Rivastigmine for dementia associated with Parkinson’s disease. N Engl J Med 351(24):2509–2518

    Article  CAS  PubMed  Google Scholar 

  • European Physiotherapy Guideline for Parkinson’s disease 2014-penultimate version for review. KnGF/ParkinsonNet, the Netherlands. www.ParkinsonNet.info

  • Fahn S, Oakes D, Shoulson I et al (2004) Levodopa and the progression of Parkinson’s disease. N Engl J Med 351:2498–2508

    Article  CAS  PubMed  Google Scholar 

  • Farley BG, Koshland GF (2005) Training BIG to move faster: the application of the speed-amplitude relation as a rehabilitation strategy for people with Parkinson’s disease. Exp Brain Res 167:462–467

    Article  PubMed  Google Scholar 

  • Fasano A, Romito LM, Daniele A, Piano C, Zinno M, Bentivoglio AR, Albanese A (2010) Motor and cognitive outcome in patients with Parkinson’s disease 8 years after subthalamic implants. Brain 133(9):2664–2676

    Article  PubMed  Google Scholar 

  • Fietzek UM, Schroetelet FE, Ziegler K, Zwosta J, Ceballos-Baumann AO (2014) Randomized cross-over trail to investigate the efficacy of a two-week physiotherapy programme with repetitive exercises of cueing to reduce the severity of freezing of gait in patients with Parkinson’s diesease. Clin Rehabil 28(9):902–911. https://doi.org/10.1177/0269215514527299

    Article  PubMed  Google Scholar 

  • Fuente-Fernandez R. de la Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology 2012;78(10):696–670

    Article  PubMed  Google Scholar 

  • Genever RW, Downes TW, Medcalf P (2005) Fracture rates in Parkinson’s disease compared with age- and gender-matched controls: a retrospective cohort study. Age Ageing 4:21–24

    Article  Google Scholar 

  • Global-Parkinsons-Disease-Survey-Steering-Committee (2002) Factors impacting on quality of life in Parkinson’s disease: results from an international survey. Mov Disord 17:60–67

    Article  Google Scholar 

  • Goetz CG, Tanner CM, Klawans HL (1984) Bupropion in Parkinson’s disease. Neurology 34:1092–1094

    Article  CAS  PubMed  Google Scholar 

  • Haupt M, Karger A, Baumgartner D, Kuminoti D, Janner M, Schneider F (2000) Improvement of agitation and anxiety in dementia patients after psychoeducative training of their caregivers. Fortschr Neurol Psychiatr 68:216–223

    Article  CAS  PubMed  Google Scholar 

  • Hely MA, Morris JG, Reid WG, Trafficante R (2005) Sydney Multicenter Study of Parkinson’s disease: non-L-Dopa-responsive problems dominate at 15 years. Mov Disord 20:190–199

    Article  PubMed  Google Scholar 

  • Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson’s disease: the inevitability of dementia at 20 years. Mov Disord 23:837–844

    Article  PubMed  Google Scholar 

  • Hoehn MM (1992) The natural history of Parkinson’s disease in the pre-levodopa eras. Neurol Clin 10:331–340

    Article  CAS  PubMed  Google Scholar 

  • Hughes AJ, Lees AJ, Stern GM (1991) Challenge tests to predict the dopaminergic response in untreated Parkinson’s disease. Neurology 41:1723–1725

    Article  CAS  PubMed  Google Scholar 

  • Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a cli nico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Jöbges M, Heuschkel G, Pretzel C, Illhardt C, Renner C, Hummelsheim H (2004) Repetitive training of compensatory steps: a therapeutic approach for postural instability in Parkinson’s disease. J Neurol Neurosurg Psychiatry 75:1682–1687

    Article  PubMed  PubMed Central  Google Scholar 

  • Katzenschlager R, Hughes A, Evans A et al (2005) Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson’s disease: a prospective study using single-dose challenges. Mov Disord 20(2):151–157

    Article  PubMed  Google Scholar 

  • Klockgether T, Wullner U, Steinbach JP, Petersen V, Turski L, Loschmann PA (1996) Effects of the antiparkinsonian drug budipine on central neurotransmitter systems. Eur J Pharmacol 301:67–73

    Article  CAS  PubMed  Google Scholar 

  • Kolk NM van der, de Vries NM, Kessels RPC, Joosten H, Zwinderman AH, Post B et al (2019). Effectiveness of home-based and remotely supervised aerobic exercise in Parkinson’s disease: a double-blind, randomised controlled trail. Lancet Neurol 18(11):998–1008. https://doi.org/10.1016/S1474-4422(19)30285-6

    Article  PubMed  Google Scholar 

  • Koller WC, Hutton JT, Tolosa E, Capilldeo R (1999) Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 53:1012–1019

    Article  CAS  PubMed  Google Scholar 

  • Krack P, Batir A, Van Blercom N et al (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson’s disease. N Engl J Med 349:1925–1934

    Article  CAS  PubMed  Google Scholar 

  • Kurlan R, Cummings J, Raman R, Thal L (2007) Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 68:1356–1363

    Article  CAS  PubMed  Google Scholar 

  • Lemke MR, Ceballos-Baumann AO (2002) Depression bei Parkinson-Patienten. Dtsch Arztebl 99:A2625–A2631

    Google Scholar 

  • Leplow B (2007) Parkinson. Hogrefe, Basel

    Google Scholar 

  • Limousin P, Pollack P, Benazzouz A et al (1995) Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 345:91–95

    Article  CAS  PubMed  Google Scholar 

  • Macht M, Ellgring H (2003) Psychologische Interventionen bei der Parkinson-Erkrankung. In: Ein Behandlungsmanual. Kohlhammer, Stuttgart

    Google Scholar 

  • Maidment I, Fox C, Boustani M (2006) Cholinesterase inhibitors for Parkinson’s disease dementia. Cochrane Database Syst Rev. CD004747

    Google Scholar 

  • McIntosh GC, Brown SH, Rice RR, Thaut MH (1997) Rhythmic auditory-motor facilitation of gait patterns in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 62:22–26

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • McKeith IG, Dickson DW, Lowe J et al (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872

    Article  CAS  PubMed  Google Scholar 

  • Mehrholz J, Kugler J, Storch A, Pohl M, Hirsch K, Elsner B (2015) Treadmill training for patients with Parkinson’s disease. Cochrane Database Syst Rev 9. "https://doi.org/CD007830". https://doi.org/10.1002/14651858.CD007830.pub4

  • Morris ME, Iansek R, Matyas TA, Summers JJ (1996) Stride length regulation in Parkinsons’s disease. Normalication strategies and underlying mechanisms. Brain 119(Pt 2):551–568

    Article  PubMed  Google Scholar 

  • Muslimovic D, Post B, Speelman JD, Schmand B, de Haan RJ (2008) Determinants of disability and quality of life in mild to moderate Parkinson disease. Neurology 70:2241–2247

    Article  CAS  PubMed  Google Scholar 

  • Oertel W, Poewe W, Wolters E et al (2008) Effects of rivastigmine on tremor and other motor symptoms in patients with Parkinson’s disease dementia: a retrospective analysis of a double-blind trial and an open-label extension. Drug Saf 31:79–94

    Article  CAS  PubMed  Google Scholar 

  • Olanow CW, Rascol O, Hauser R et al (2009) A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 361:1268–12678

    Article  CAS  PubMed  Google Scholar 

  • Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G (2005) Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s disease. Mov Disord 20:958–963

    Article  PubMed  Google Scholar 

  • Onofrj M, Luciano AL, Thomas A, Iacono D, D’Andreamatteo G (2003) Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. Neurology 60:113–115

    Article  CAS  PubMed  Google Scholar 

  • Pahwa R, Tanner CM, Hauser RA, Isaacson SH, Nausieda PA, Truong DD et al (2017) ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): a randomized clinical trial. JAMA Neurol 74(8):941–949

    Article  PubMed  PubMed Central  Google Scholar 

  • Perlmutter JS, Eidelberg D (2012) To scan or not to scan: DaT is the question. Neurology 78(10):688–689

    Article  PubMed  Google Scholar 

  • Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W et al (2015) MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord 30(12):1591–1560

    Article  PubMed  Google Scholar 

  • Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C (2007) Effect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ duration. Mov Disord 22:313–318

    Article  PubMed  Google Scholar 

  • Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF (2008) A systematic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 23:183–189; quiz 313

    Article  PubMed  Google Scholar 

  • Richard IH, Kurlan R (1997) A survey of antidepressant drug use in Parkinson’s disease. Parkinson Study Group. Neurology 49:1168–1170

    Article  CAS  PubMed  Google Scholar 

  • Rijk MC de, Launer LJ, Berger K et al (2000) Prevalence of Parkinson’s disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54: S21–S23

    Google Scholar 

  • Riley D, Lang AE, Blair RDG et al (1988) Frozen shoulder and other shoulder abnormalities in Parkinson’s disease. J Neurol Neurosurg Psychiatry 52:63–66

    Article  Google Scholar 

  • Sakakibara R, Shinotoh H, Uchiyama T et al (2001) Questionnaire-based assessment of pelvic organ dysfunction in Parkinson’s disease. Auton Neurosci 92:76–85

    Article  CAS  PubMed  Google Scholar 

  • Samuel M, Rodriguez-Oroz M, Antonini A, Brotchie JM, Ray Chaudhuri K, Brown RG, Galpern WR, Nirenberg MJ, Okun MS, Lang AE (2015) Management of impulse control disorders in Parkinson’s disease: controversies and future approaches. Mov Disord 30(2):150–159

    Article  PubMed  PubMed Central  Google Scholar 

  • Schoffer KL, Henderson RD, O’Maley K, O’Sullivan JD (2007) Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson’s disease. Mov Disord 22(11):1543–1549

    Article  PubMed  Google Scholar 

  • Schrag A, Quinn N (2000) Dyskinesias and motor fluctuations in Parkinson’s disease. A community-based study. Brain 2000 123(Pt 11):2297–2305

    Google Scholar 

  • Schroeteler FE, Fietzek UM, Ziegler K, Ceballos-Baumann AO (2011) Upright posture in parkinsonian camptocormia using a high-frame walker with forearm support. Mov Disord 26(8):1560–1561

    Article  PubMed  Google Scholar 

  • Schenkman M, Moore CG, Kohrt WM, Hall DA, Delitto A, Camella CL et al (2018) Effect of high-intensity treadmill exercise on motor symptoms in patients with de novo Parkinson disease: a phase 2 randomized clinical trail. JAMA Neurol 75(2):219. https://doi.org/10.1001/jamaneurol.2017.3517

    Article  PubMed  Google Scholar 

  • Schroeteler F, Ceballos-Baumann A (2016) Münchner Anti Freezing Training (MAFT). Nervenheilkunde 34:198–204

    Google Scholar 

  • Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L et al (2013) Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med 368(7):610–622

    Article  CAS  PubMed  Google Scholar 

  • Singer W, Sandroni P, Opfer-Gehrking TL et al (2006) Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 63:513–518

    Article  PubMed  Google Scholar 

  • Storch A, Odin P, Trender-Gerhard I et al (2010) Non-motor Symptoms Questionnaire and Scale for Parkinson’s disease. Cross-cultural adaptation into the German language. Nervenarzt 81:980–985

    Article  CAS  PubMed  Google Scholar 

  • Suteerawattananon M, Morris GS, Etnyre BR, Jankovic J, Protas EJ (2004) Effects of visual and auditory cues on gait in individuals with Parkinson’s disease. J Neurol Sci 219:63–69

    Article  CAS  PubMed  Google Scholar 

  • Tanner CM (1994) Epidemiological clues to the cause of Parkinson’s disease. In: Marsden CD (Hrsg) Movement disorders, Bd 3. Butterworths, London, S 124–146

    Google Scholar 

  • Thomas A, Iacono D, Luciano AL, Armellino K, Di Iorio A, Onofrj M (2004) Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease. J Neurol Neurosurg Psychiatry 75:141–143

    CAS  PubMed  PubMed Central  Google Scholar 

  • Tönges L, Ceballos-Baumann A, Honig H, Storch A, Jost WH (2017) Praktische Anwendung der kontinuierlichen Apomorphin-Pumpentherapie. Fortsch Neuro Psych 85:516

    Article  Google Scholar 

  • Wagner-Sonntag E (2008) Schluckstörungen bei Parkinson-Syndromen. In: Ceballos-Baumann A, Ebersbach G (Hrsg) Aktivierende Therapien bei Parkinson-Syndromen. Thieme, Stuttgart, S 31–39

    Google Scholar 

  • Walker Z, Possin KL, Boeve BF, Aarsland D (2015) Lewy body dementias. Lancet 386(10004):1683–1697

    Article  PubMed  PubMed Central  Google Scholar 

  • Weaver FM, Follett K, Stern M et al (2009) Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 301:63–73

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wegen E van, de Goede C, Lim I et al (2006) The effect of rhythmic somatosensory cueing on gait in patients with Parkinson’s disease. J Neurol Sci 248(1–2): 210–214

    Google Scholar 

  • Weintraub D, Koester J, Potenza MN et al (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67:589–595

    Article  PubMed  Google Scholar 

  • Willems AM, Nieuwboer A, Chavret F et al (2007) Turning in Parkinson’s disease patients and controls: the effect of auditory cues. Mov Disord 22:187–188

    Article  Google Scholar 

  • Williams A, Gill S, Varma T et al (2010) Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 9:581–591

    Article  PubMed  PubMed Central  Google Scholar 

  • Ypinga JHL, de Vries NM, Boonen LHHM, Kooman X, Munneke M, Zwinderman AH et al (2018) Effectiveness and costs of specialised physiotherapy given via PArkinsonNet: a retrospective analysis of medical claims data. Lancet Neurol 17(2):153–161. https://doi.org/10.1016/S1474-4422(17)30406-4

    Article  PubMed  Google Scholar 

  • Ziegler K, Schroeteler F, Ceballos-Baumann AO, Fietzek UM (2010) A new rating instrument to assess festination and freezing gait in Parkinsonian patients. Mov Disord 25(8):1012–1018

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Parkinson-Fachklinik, Schön Klinik München Schwabing, München, Deutschland

    Andrés Ceballos-Baumann

Authors
  1. Andrés Ceballos-Baumann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrés Ceballos-Baumann .

Editor information

Editors and Affiliations

  1. Essen, Germany

    Peter Berlit

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Ceballos-Baumann, A. (2018). Idiopathisches Parkinson-Syndrom (IPS). In: Berlit, P. (eds) Klinische Neurologie. Springer Reference Medizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-44768-0_129-1

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-44768-0_129-1

  • Received:

  • Accepted:

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-44768-0

  • Online ISBN: 978-3-662-44768-0

  • eBook Packages: Springer Referenz Medizin

Publish with us

Policies and ethics

Search

Navigation